In today’s world, life sciences IT strategy is now a board-level initiative.

Life sciences CIOs face a twin mandate. They must help R&D materially improve productivity while helping to deliver safe, effective therapies to patients faster.

However, life sciences IT challenges are not simple to solve. On the one hand, we see compressed cycle times, diversification into novel modalities, and shifting evidence standards. On the other hand, there are legacy data silos and costly validation approaches.

The result is an execution gap that life sciences software can close. However, those solutions should be delivered on modern platforms, governed to GxP expectations, and aligned tightly to business outcomes.

There are eight strategic trends shaping life sciences IT strategy.  From those eight trends we can define a pragmatic playbook to align platforms, data, AI, and compliance with measurable value.

1. End-to-end data platforms and FAIR-by-design

The fastest-moving companies are converging R&D, clinical, quality, manufacturing, and commercial data onto governed, cloud-native platforms. Then, they make the data FAIR (Findable, Accessible, Interoperable, Reusable) by design. Practically, that means adopting interoperability standards such as HL7 FHIR for healthcare data, CDISC SDTM/ADaM for clinical research, and IDMP (via EMA SPOR) for product master data. Also, ensure data integrity under ALCOA+ expectations from MHRA and others. This foundation accelerates analytics and AI reuse, improves traceability, and reduces time-to-insight across the lifecycle.

Hyperscaler health data platforms reinforce this trend. Options include Google Cloud Healthcare Data Engine, Microsoft Azure Health Data Services, Databricks and Snowflake. They combine standards-native storage, de-identification, governance, and scalable analytics. Novartis’ Data42 illustrates the payoff. A FAIR enterprise platform integrating decades of R&D and clinical data to improve discoverability and accelerate analytics and AI—built with strong governance and a capability-driven operating model.

2. AI at scale across the value chain (from discovery to PV)

Generative AI and advanced analytics are shifting from pilots to platforms. Estimates from McKinsey suggest AI could unlock $60–$110 billion annually in value for pharma—if scaled responsibly, with the right operating models and data foundations. Impact spans discovery (target identification and design), clinical development (protocol authoring, site selection, monitoring), pharmacovigilance (NLP for case intake and triage), labeling, and field engagement.

Real signals point to AI’s mainstreaming. Isomorphic Labs’ multi-year collaborations with Novartis and Eli Lilly highlight AI-first discovery at enterprise scale. Sanofi’s alliance with OpenAI and Formation Bio aims to build an AI-enabled development platform and deploy R&D copilots. NVIDIA’s investment in Recursion underscores the infrastructure needs to scale generative AI for biology using platforms like BioNeMo.

The implications for life sciences IT strategy are concrete. High-quality proprietary data, MLOps with GxP controls (model cards, lineage, validation), and AI governance are aligned to the EU AI Act and, for device contexts, FDA’s SaMD PCCP draft.

3. Decentralized and hybrid clinical trials with digital endpoints

Clinical development is embracing decentralized and hybrid models at scale to broaden access, reduce patient burden, and capture continuous data. The FDA has provided definitive guidance on decentralized clinical trials (DCTs) and on digital health technologies (DHTs) for remote data acquisition. In parallel, the agency finalized guidance on using EHR and medical claims data in clinical studies. Together, these clarify selection and validation of wearables and sensors, identity, consent, data management, cybersecurity, and traceability.

Validated stacks from providers like IQVIA Decentralized Trials and Medidata DCT combine eConsent, eCOA, sensors, telemedicine, and remote monitoring. They often achieve faster enrollment and better retention in hybrid models. For  effective life sciences IT strategy, the architecture must support secure identity, privacy-preserving data ingestion at scale, data reconciliation across modalities, and audit-ready pipelines, especially when DCTs feed real-world evidence (RWE) programs.

4. Digital quality and risk-based validation (CSA) in GxP

Moving from document-heavy CSV to risk-based, automated assurance is pivotal for cloud adoption in regulated workloads. The FDA’s final guidance on Computer Software Assurance (CSA) emphasizes intended use and risk to patient safety/product quality. The FDA encourages flexible assurance activities such as unscripted and automated testing, which reduce paperwork while increasing confidence. This is essential for frequent SaaS updates in QMS, EBR, LIMS, and cloud data platforms.

SaaS vendors are adapting. Veeva Vault Quality and partners like MasterControl’s CSA guide provide accelerators to transition from CSV to CSA, improving release cadence without compromising compliance. In our view, teams that operationalize CSA with automated evidence capture and traceability unlock both speed (for example, review-by-exception batch release) and audit readiness, turning “compliance-by-design” into a competitive advantage.

5. Connected, compliant cloud for smart manufacturing (Pharma 4.0)

Pharma 4.0 isn’t just a buzzword. It’s a blueprint for digital manufacturing maturity spanning MES-EBR-QMS-ERP integration, PAT, advanced process control, and digital twins. The ISPE Pharma 4.0 initiative outlines the target state for connected plants that improve yield, reduce deviations, and shorten batch-release times, especially important in biologics and emerging modalities. Edge-cloud architectures and validated data pipelines are non-negotiable to bring analytics to the shop floor and maintain data integrity.

A notable case is Moderna’s cloud-native manufacturing backbone. Partnering with AWS, Moderna scaled mRNA vaccine production using GxP-compliant workloads on AWS, electronic batch records, and integrated quality, accelerating safe batch release.

For life sciences CIOs, the takeaway is clear. That is, marry modern cloud services with validation patterns and plant-floor integration to digitize tech transfer and release-by-exception at scale.

6. Supply chain resiliency and DSCSA compliance

Supply chain transparency moved from aspiration to obligation. With the FDA’s DSCSA now in effect, trading partners are expected to implement interoperable, electronic, unit-level traceability and verification (FDA DSCSA law and policies). This requires serialization data quality, event-driven collaboration across L2–L5 partners, and robust exception handling to safeguard patient safety and manage returns.

Enterprise serialization backbones such as SAP Advanced Track and Trace for Pharmaceuticals help orchestrate DSCSA and FMD compliance, including EPCIS event interchange with wholesalers and dispensers.

For life sciences IT strategy, the focus is integrating serialization with ERP, warehouse systems, and partner networks. Moreover, this includes monitoring data quality and designing for resiliency against shortages and disruptions.

7. Security and privacy by design (Zero Trust, de-identification)

As data volumes and external collaborations grow, protecting PHI/PII, trade secrets, and clinical data is existential. A Zero Trust Architecture (NIST SP 800-207) with attribute-based access control, continuous verification, and least privilege is now the baseline. In addition, device and digital product teams must also meet stricter obligations. For example, the FDA’s medical device cybersecurity requirements (Section 524B) address SBOMs and vulnerability management across the lifecycle.

Privacy-preserving analytics at scale are also maturing. Clean-room capabilities such as AWS Clean Rooms for Healthcare & Life Sciences and those in Snowflake enable governed, query-restricted collaboration with partners for RWE and commercial use cases—without sharing raw PHI. In our opinion, organizations that embed privacy engineering (tokenization, de-identification, synthetic data) into pipelines will collaborate faster and safer.

8. Evidence acceleration with real-world evidence (RWE)

Regulators are increasingly clear about when and how RWD can support decisions. The FDA’s RWE Program and series of guidances—including on EHR and claims data use—emphasize data quality, traceability, and fit-for-purpose study design. For example, the EMA’s DARWIN EU network is building a federated RWE infrastructure to provide timely, reliable evidence across the lifecycle.

For IT, the implications include standardizing ingestion from EHR/claims/registries, implementing causal inference workflows, maintaining audit-ready lineage and consent traceability, and supporting federated analytics. Then, success unlocks faster indication expansion, more efficient post-marketing commitments, and improved pharmacovigilance signal triage.

Watch for the following emerging priorities.

• Advanced modalities (cell/gene therapy, RNA, radiopharma) demand chain-of-identity/custody, vein-to-vein orchestration, and small-batch QA—requiring fit-for-purpose IT.
• Software as a Medical Device (SaMD) and companion apps are new revenue streams.  AI-enabled SaMD’s should plan for the EU AI Act’s high-risk obligations and. In the US, plan for the FDA’s PCCP framework.
• Deloitte’s life sciences outlooks highlights ESG and sustainable IT/OT. Carbon-aware workloads, lab energy optimization, and green data centers can reduce cost and support disclosure commitments.

From business strategy to life sciences IT strategy — an alignment playbook

High-performing life sciences CIOs anchor technology decisions to value streams: Discover, Develop, Make, and Deliver/Engage. Start with a capability map that expresses where the business must win. (For example, “reduce time-to-first-patient by 20%” or “cut batch release time by 30%”). Then translate these ambitions into action.

In our view, a concise capability map—shared across R&D, Clinical, Quality, Manufacturing, and Commercial—is the north star.

Choose platforms and architectures that you can support for a decade. Standardize on a small set of enterprise platforms for data/AI (Databricks, Snowflake), clinical operations (Veeva, Medidata), quality and regulatory (like Veeva Development Cloud), and manufacturing (MES/EBR/QMS integrated per ISPE Pharma 4.0). Establish GxP and non-GxP reference patterns: lineage and audit trails, PHI-aware tagging and de-identification, and MLOps with GxP controls. For ecosystem collaboration and RWE, add privacy-safe patterns such as AWS Clean Rooms.

Operationalize data governance and compliance-by-design. Make FAIR real with data product SLAs (quality, timeliness, completeness and interoperability via HL7 FHIR, CDISC, and IDMP/SPOR). Apply FDA CSA to validate intended use and risk. And automate testing and evidence capture (e.g., MasterControl’s CSA guide). For AI governance, ensure clear documentation, oversight, and vendor risk management, per the EU AI Act. For device contexts, incorporate SaMD PCCP. Embed Zero Trust security and privacy engineering into design.

Build the operating model to sustain change. Product-centric teams blending domain scientists, data/ML engineers, QA/CSV, and cybersecurity are better than functional silos. Empower them with self-service sandboxes and AI copilots (like Sanofi’s AI-enabled development platform).

Use TBM practices to align spend to value streams, stage-gate investments, and track realized benefits (for example, protocol finalization cycle time, deviations per batch, % PV cases processed with NLP). In our opinion, the combination of platform discipline, CSA-enabled speed, and ruthless outcome focus is what separates pilots from lasting impact.

Conclusion: turn life sciences IT strategy into repeatable, compliant execution

The life sciences IT strategy imperative is clear.

Platformize data with FAIR-by-design, scale AI with robust MLOps and governance, digitize quality and manufacturing under CSA, modernize trials with DCT/DHT patterns, secure the ecosystem with Zero Trust, and accelerate RWE with audit-ready pipelines.

The signals—from McKinsey’s $60–$110B AI value estimate to the FDA’s final guidance on CSA, DCTs, DHTs, and EHR/claims, and the EU’s AI Act—all point in the same direction.